Eiji Miyoshi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6907628/publications.pdf Version: 2024-02-01



ЕШ Міхосні

#	Article	IF	CITATIONS
1	Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer. British Journal of Cancer, 2022, 126, 764-770.	2.9	7
2	<i>Enterococcus</i> spp. have higher fitness for survival, in a <scp>pH</scp> â€dependent manner, in pancreatic juice among duodenal bacterial flora. JCH Open, 2022, 6, 85-90.	0.7	6
3	Establishment of monoclonal antibodies broadly neutralize infection of hepatitis B virus. Microbiology and Immunology, 2022, , .	0.7	2
4	Serum Macâ€2 binding protein level predicts the development of liverâ€related events and colorectal cancer in patients with NAFLD. Hepatology Communications, 2022, 6, 1527-1536.	2.0	3
5	Proscillaridin A Sensitizes Human Colon Cancer Cells to TRAIL-Induced Cell Death. International Journal of Molecular Sciences, 2022, 23, 6973.	1.8	0
6	The blockade of interleukinâ€33 released by hepatectomy would be a promising treatment option for cholangiocarcinoma. Cancer Science, 2021, 112, 347-358.	1.7	6
7	Rab11-mediated post-Golgi transport of the sialyltransferase ST3GAL4 suggests a new mechanism for regulating glycosylation. Journal of Biological Chemistry, 2021, 296, 100354.	1.6	13
8	Identification of fucosylated haptoglobinâ€producing cells in pancreatic cancer tissue and its molecular mechanism. Glycoconjugate Journal, 2021, 38, 45-54.	1.4	6
9	Serum coreâ€ŧype fucosylated prostateâ€specific antigen index for the detection of highâ€risk prostate cancer. International Journal of Cancer, 2021, 148, 3111-3118.	2.3	12
10	Branched-chain amino acids protect the liver from cirrhotic injury via suppression of activation of lipopolysaccharide-binding protein, toll-like receptor 4, and signal transducer and activator of transcription 3, as well as Enterococcus faecalis translocation. Nutrition, 2021, 86, 111194.	1.1	13
11	Challenges in the Application of Glyco-Technology to Hepatitis B Virus Therapy and Diagnosis. Viruses, 2021, 13, 1860.	1.5	2
12	Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis. World Journal of Gastroenterology, 2021, 27, 162-175.	1.4	8
13	Fucosylation in Urological Cancers. International Journal of Molecular Sciences, 2021, 22, 13333.	1.8	5
14	Functional glycomics: Application to medical science and hepatology. Hepatology Research, 2020, 50, 153-164.	1.8	17
15	Loss of Rab6a in the small intestine causes lipid accumulation and epithelial cell death from lactation. FASEB Journal, 2020, 34, 9450-9465.	0.2	1
16	High Dye-Loaded and Thin-Shell Fluorescent Polymeric Nanoparticles for Enhanced FRET Imaging of Protein-Specific Sialylation on the Cell Surface. Analytical Chemistry, 2020, 92, 13271-13280.	3.2	16
17	Oligosaccharideâ€dependent antiâ€inflammatory role of galectinâ€1 for macrophages in ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 2158-2169.	1.4	5
18	Loss of core fucosylation reduces low-density lipoprotein receptor expression in hepatocytes by inducing PCSK9 production. Biochemical and Biophysical Research Communications, 2020, 527, 682-688.	1.0	0

Еіјі Міуозні

#	Article	IF	CITATIONS
19	Serum Mac-2 Binding Protein Levels Associate with Metabolic Parameters and Predict Liver Fibrosis Progression in Subjects with Fatty Liver Disease: A 7-Year Longitudinal Study. Nutrients, 2020, 12, 1770.	1.7	11
20	The Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectinâ€1. Angewandte Chemie - International Edition, 2019, 58, 18697-18702.	7.2	29
21	The Core Fucose on an IgG Antibody is an Endogenous Ligand of Dectinâ€1. Angewandte Chemie, 2019, 131, 18870-18875.	1.6	2
22	Establishment and characterization of a fucosylated α-fetoprotein-specific monoclonal antibody: a potential application for clinical research. Scientific Reports, 2019, 9, 12359.	1.6	15
23	Development of αâ€Gal–Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. Angewandte Chemie, 2019, 131, 4574-4578.	1.6	6
24	Development of αâ€Gal–Antibody Conjugates to Increase Immune Response by Recruiting Natural Antibodies. Angewandte Chemie - International Edition, 2019, 58, 4526-4530.	7.2	23
25	Characterisation of N-glycans in the epithelial-like tissue of the rat cochlea. Scientific Reports, 2019, 9, 1551.	1.6	4
26	Core fucose is essential glycosylation for CD14-dependent Toll-like receptor 4 and Toll-like receptor 2 signalling in macrophages. Journal of Biochemistry, 2019, 165, 227-237.	0.9	22
27	The Rab11-binding protein RELCH/KIAA1468 controls intracellular cholesterol distribution. Journal of Cell Biology, 2018, 217, 1777-1796.	2.3	43
28	Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. Biochemical and Biophysical Research Communications, 2018, 506, 962-969.	1.0	69
29	Development of α1,6-fucosyltransferase inhibitors through the diversity-oriented syntheses of GDP-fucose mimics using the coupling between alkyne and sulfonyl azide. Bioorganic and Medicinal Chemistry, 2017, 25, 2844-2850.	1.4	12
30	Core fucose is critical for CD14-dependent Toll-like receptor 4 signaling. Glycobiology, 2017, 27, 1006-1015.	1.3	32
31	Use of Macâ€2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatology Communications, 2017, 1, 780-791.	2.0	38
32	Establishment of mouse Macâ€⊋ binding protein enzymeâ€linked immunosorbent assay and its application for mouse chronic liver disease models. Hepatology Research, 2017, 47, 902-909.	1.8	11
33	Mac-2 Binding Protein is a Useful Liver Fibrosis Biomarker for NAFLD/NASH. Trends in Glycoscience and Glycotechnology, 2017, 29, E85-E92.	0.0	1
34	A glycoproteomic approach to identify novel glycomarkers for cancer stem cells. Proteomics, 2016, 16, 3073-3080.	1.3	6
35	Ectopic expression of <i>N</i> â€acetylglucosaminyltransferase V accelerates hepatic triglyceride synthesis. Hepatology Research, 2016, 46, E118-29.	1.8	4
36	Glyco-redox, a link between oxidative stress and changes of glycans: Lessons from research on glutathione, reactive oxygen and nitrogen species to glycobiology. Archives of Biochemistry and Biophysics, 2016, 595, 72-80.	1.4	31

Еіјі Міуозні

#	Article	IF	CITATIONS
37	Role of aberrant IgC glycosylation in the pathogenesis of inflammatory bowel disease. Proteomics - Clinical Applications, 2016, 10, 384-390.	0.8	22
38	Application of glycoscience to the early detection of pancreatic cancer. Cancer Science, 2016, 107, 1357-1362.	1.7	23
39	Hepatic aberrant glycosylation by <i>N</i> -acetylglucosaminyltransferase V accelerates HDL assembly. American Journal of Physiology - Renal Physiology, 2016, 311, G859-G868.	1.6	4
40	Core-fucosylation plays a pivotal role in hepatitis B pseudo virus infection: a possible implication for HBV glycotherapy. Glycobiology, 2016, 26, 1180-1189.	1.3	17
41	Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer. Glycoconjugate Journal, 2016, 33, 471-482.	1.4	40
42	Elevation of CA19-9-Related Novel Marker, Core 1 Sialyl Lewis A, in Sera of Adenocarcinoma Patients Verified by a SRM-Based Method. Journal of Proteome Research, 2016, 15, 152-165.	1.8	10
43	Core Fucosylation on T Cells, Required for Activation of T-Cell Receptor Signaling and Induction of Colitis in Mice, Is Increased in Patients With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, 1620-1632.	0.6	93
44	N-Acetylglucosaminyltransferase V exacerbates murine colitis with macrophage dysfunction and enhances colitic tumorigenesis. Journal of Gastroenterology, 2016, 51, 357-369.	2.3	10
45	Decreased fucosylated PSA as a urinary marker for high Gleason score prostate cancer. Oncotarget, 2016, 7, 56643-56649.	0.8	23
46	Oligosaccharide modification by <i><scp>N</scp></i> â€acetylglucosaminyltransferaseâ€ <scp>V</scp> in macrophages are involved in pathogenesis of bleomycinâ€induced scleroderma. Experimental Dermatology, 2015, 24, 585-590.	1.4	11
47	Rab11a is required for apical protein localisation in the intestine. Biology Open, 2015, 4, 86-94.	0.6	78
48	A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology, 2015, 62, 1433-1443.	3.6	61
49	Fetuinâ€A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver International, 2015, 35, 925-935.	1.9	54
50	Establishment of a novel lectin–antibody ELISA system to determine core-fucosylated haptoglobin. Clinica Chimica Acta, 2015, 446, 30-36.	0.5	23
51	Effectiveness evaluation of waist support tool through human posture balance. , 2014, , .		2
52	A difference of human posture between beginner and expert during lifting a heavy load. , 2014, , .		3
53	Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate, 2014, 74, 1052-1058.	1.2	49
54	Pancreatic Fatty Degeneration and Fibrosis as Predisposing Factors for the Development of Pancreatic Ductal Adenocarcinoma. Pancreas, 2014, 43, 1032-1041.	0.5	57

Еіл Міуозні

#	Article	IF	CITATIONS
55	Serum Macâ€2 binding protein levels as a novel diagnostic biomarker for prediction of disease severity and nonalcoholic steatohepatitis. Proteomics - Clinical Applications, 2013, 7, 648-656.	0.8	51
56	Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS ONE, 2013, 8, e66328.	1.1	59
57	Mutation of GDP-Mannose-4,6-Dehydratase in Colorectal Cancer Metastasis. PLoS ONE, 2013, 8, e70298.	1.1	28
58	Fucosylation Is a Promising Target for Cancer Diagnosis and Therapy. Biomolecules, 2012, 2, 34-45.	1.8	132
59	Upregulation of N-acetylglucosaminyltransferase-V by heparin-binding ECF-like growth factor induces keratinocyte proliferation and epidermal hyperplasia. Experimental Dermatology, 2012, 21, 515-519.	1.4	23
60	Physiological roles of N-acetylglucosaminyltransferase V (GnT-V) in mice. BMB Reports, 2012, 45, 554-559.	1.1	21
61	Combination use of anti D133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. Cancer Science, 2011, 102, 1164-1170.	1.7	17
62	Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clinical Chemistry and Laboratory Medicine, 2011, 49, 959-66.	1.4	19
63	The effect of epigenetic regulation of fucosylation on TRAIL-induced apoptosis. Glycoconjugate Journal, 2010, 27, 649-659.	1.4	31
64	Involvement of Aberrant Glycosylation in Thyroid Cancer. Journal of Oncology, 2010, 2010, 1-7.	0.6	34
65	High levels of E4-PHA-reactive oligosaccharides: potential as marker for cells with characteristics of hepatic progenitor cells. Glycoconjugate Journal, 2009, 26, 1213-1223.	1.4	9
66	Deficiency of GMDS Leads to Escape from NK Cell-Mediated Tumor Surveillance Through Modulation of TRAIL Signaling. Gastroenterology, 2009, 137, 188-198.e2.	0.6	92
67	Fucosylated haptoglobin is a novel marker for pancreatic cancer: Detailed analyses of oligosaccharide structures. Proteomics, 2008, 8, 3257-3262.	1.3	100
68	Siteâ€specific analysis of <i>N</i> â€glycans on haptoglobin in sera of patients with pancreatic cancer: A novel approach for the development of tumor markers. International Journal of Cancer, 2008, 122, 2301-2309.	2.3	125
69	Biological Function of Fucosylation in Cancer Biology. Journal of Biochemistry, 2007, 143, 725-729.	0.9	329
70	Phenotype Changes of Fut8 Knockout Mouse: Core Fucosylation Is Crucial for the Function of Growth Factor Receptor(s). Methods in Enzymology, 2006, 417, 11-22.	0.4	72
71	From The Cover: Dysregulation of TGF-Â1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 15791-15796.	3.3	413